ASCO 2023 | IILUSTRO: zolbetuximab, mFOLFOX6, and nivolumab combinations for gastrointestinal cancer
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the Phase II ILUSTRO trial (NCT03505320), which is investigating the combination of zolbetuximab, mFOLFOX6, and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction (mG/GEJ) adenocarcinomas, with high PD-L1 expression. In previous dosing schedules from previous trials, zolbetuximab was administered fortnightly, However, zolbetuximab was administered every two weeks to fall in line with mFOLFOX6 administration in this trial which is currently ongoing. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Read more...
More from Kohei Shitara
Related Videos
Cookie settings
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.